Enliven Therapeutics ELVN EBITDA

EBITDA at other companies

Bristol-Myers SquibbBMY

$4.68B+68.1%

PfizerPFE

$4.78B+8.6%

ImmunityBio, Inc.IBRX

-$65.41M-7.9%

Iovance Biotherapeutics, Inc.IOVA

-$48.12M+56.4%

Syndax PharmaceuticalsSNDX

-$30.2M+63.9%

Cullinan Therapeutics, Inc.CGEM

-$57.18M+24.5%

FAQ

What is Enliven Therapeutics's EBITDA?

Enliven Therapeutics (ELVN) reported EBITDA of -$27.81M in Q1 2026.

How has Enliven Therapeutics's EBITDA changed year-over-year?

Enliven Therapeutics's EBITDA increased by 12.0% year-over-year, from -$31.62M to -$27.81M.

What is the long-term trend for Enliven Therapeutics's EBITDA?

Over 4 years (2021 to 2025), Enliven Therapeutics's EBITDA has grown at a 23.5% compound annual growth rate (CAGR), from -$51.34M to -$119.4M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.